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 ABSTRACT  
Somatic mosaicism is  the presence of genetically diverse  lineage of somatic cells within 
an organism even though deriving from a single zygote. Mosaicism is known to occur in 
many  diseases.  Breast  cancer  is  the  second most  cause  of  deaths  in woman  caused  by 
malignant tumor. Breast cancer was a common malignancy and main cause of morbidity 
and disease related mortality among women. By studying the genetic profiles of the cells 
surrounding the primary tumor and blood of same patient may reveal the cause of tumor 
cells.  The  purpose  of  this  study  was  to  identify  the  presence  of  somatic  mosaicism  in 
healthy uninvolved margin of breast tissue surrounding the primary tumor and blood of 
breast cancer patient by using Illumina 1M BeadChip and Nimblegen 720K array.   
So  far, all  long and very rigorous research explains only 10% of  the breast cancer. This 
indicates  the  complexity  of  cancer  and  the  factors  responsible  for  the  development  of 
tumor  in  healthy  tissues.  Results  from  whole  genome  genotyping  by  Illumina  1M 
beadchip of blood and cells surrounding the primary tumor of same patient indicate the 
presence  of  somatic  mosaicism  in  chromosome  6,  8  and  18  of  ML36B  (uninvolved 
margin),  ML36A2  and  ML36A3  (primary  tumor)  which  was  confirmed  by  genotyping 
with  Nimblegen  720K  microarrays.  Genotyping  also  showed  the  presence  of  genomic 
imbalance in genetic makeup of the healthy tissue surrounding the primary tumor.          
It  is  to be  likely  that  rate of discovery of  somatic mosaicism  in  the  small proportion of 
studies cells might continue to accelerate the studies on genetic heterogeneity of breast 
malignancies. As well as studies by comparing the genetic profiles of tumours and tissue 
surrounding the primary tumour may lead to identify the genomic aberrations in context 
to cancer progression.    
 
 
 
 
 
 
 
  
 ABBREVIATIONS  
BRCA     Breast cancer susceptibility gene 
cDNA     complementary Deoxyribonucleic acid 
CGH      Comparative Genomic Hybridization 
DNA     Deoxyribo Nucleic acid 
EDTA      Ethylenediaminetetra acetic acid 
EGF      Epidermal growth factor 
ERBB     Avian erythroblastosis oncogene B 
FAH     Fumarylaceto acetate hydrolase 
gDNA     Genomic Deoxyribonucleic acid 
LOH      Loss of Heterozygosity  
NaAc     Sodium acetate  
NaCl     Sodium chloride  
PBS      Sodium perborate 
PTEN     Phosphatase and tensin homolog 
rpm      Revolutions per minute 
SNP     Single nucleotide polymorphism 
TGFβ      Transforming Growth Gactor beta 
WGG       Whole Genome Genotyping 
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INTRODUCTION 
Cancer 
Cancer is a class of genetic disease that evolves through genetic alterations. During last 
decades the extensive research of molecular mechanism of tumour formation has broadened 
our knowledge about tumour formation[1]. The generation of cancer is due to the alteration in 
three types of gene families: proto oncogenes, tumour suppressor genes and stability genes [2]. 
The normal function of proto oncogenes is to promote cell growth or survival, when mutated or 
expressed at high levels can cause tumour formation. The functional absence of tumour 
suppressor genes can lead to cancer. Carcinogenic mutation in these genes may result in 
inactive gene or gene products which are then unable to inhibit cell growth. The stability genes 
also known as caretaker genes are types of genes responsible for DNA repair. When stability 
genes are inactivated, mutation occurs at higher rates in other genes and genetic rates can’t be 
controlled [2].   
A single mutation cannot transform normal cell to a cancer cell as there are safeguard 
mechanisms existing. For example two genetic alterations is required for cultured rodent cells 
where as human cells require at least three genetic alterations [3]. 
All the cells have multiple control systems. When these control systems are disrupted it always 
leads to tumour development. These genetic changes include evasion of apoptosis, tissue 
invasion and metastasis, self-sufficiency in growth signals, block of differentiation, limitless 
replicative potential, sustained angiogenesis and genomic instability (Figure 1) [1].  
 
 
Figure 1. Schematic diagram of cellular process affected by genetic alterations in cancer cells.  
However cancer in fundamental nature is a disease in which environmental factors and causal 
genetic abnormalities act together [4].  Most of mutations in cancer occur in somatic cells and 
are not inherited to next generation. On the other hand inherited mutations that are carried in 
germ line may influence cells to tumorigenesis specially when combined with somatic 
mutation. Somatic mutation include several classes of DNA changes such as insertion or 
deletion of DNA fragments, copy number increases and reductions, base substitution and 
chromosomal rearrangements [5]. Projects that resequence tumour genomes have analytically 
discovered thousands of genes which are not linked to tumorigenesis but in a small fraction 
they are somatically mutated and may be vital for tumour progression and initiation [6-11]. 
Several of these somatic changes are expected to be passengers which have no functional 
effects but are already present in cell that rise to tumour or acquire during tumour growth [6].  
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The most pressing challenge in cancer genetics is determining mutations which are drivers and  
passengers. Driver genes are mutated very frequently and genes which are discovered thus far 
are mutated in a relatively small fraction of tumours [6]. The examination of large number of 
tumour can give information for classification of drivers versus passengers, but capability of 
sequencing alone to give definite results is limited due to variation in mutation frequency in 
individual tumours and individual genes [6]. 
 
Breast Cancer 
Breast cancer constitutes 10.4% of all cancer prevalence worldwide among women and it is the 
second common type of non-skin cancer and fifth common causes of cancer deaths [12].  The 
cancer that originates from epithelium of glandular tissue, most commonly from lobules which 
are milk-producing glands or ducts which produce milk to nipple is referred as breast cancer 
(Figure 2). The carcinomas that originate from ducts are called ductal carcinomas and 
carcinomas that originate from lobules are called lobular carcinomas. 
Breast tumours can be classified histologically into invasive or non-invasive (in situ) 
carcinoma. Invasive ductal carcinoma is the most common of all cases and it accounts for 80% 
[13]. Cancer cells can attack nearby healthy breast tissue and metastasize to lymph nodes. 
Through spreading via lymph nodes or blood they can spread to other distal parts of the body 
[14]. The fatal outcome of the disease is caused by the metastatic spread of tumour cells. 
 
 
Figure 2. Breast anatomy.  A milk ducts, B milk lobules, C dilated section of duct to hold milk, D nipple and 
areola, E fatty tissue, F pectoralis major muscle, G chest wall/rib cage; Enlargement: A normal duct cells, 
B basement membrane, C lumen (center of duct). Adapted and modified from 
http://www.breastcancer.org/illustrations/i0013.html. 
 
Like many other malignancies, breast cancer also results from stepwise genetic alterations of 
host cells and from other epigenetic changes in the behavior of not only cancer cells but also 
the host cells which interact with the tumor, like vascular, immune and stromal cells [15]. 
However, only a small proportion of breast cancer can be attributed to inherited mutation. 
Around 5-10% of mutations causing breast cancer are due to the inactivation of autosomal 
dominant genes: BRCA1 and BRAC2 the breast cancer susceptibility genes. BRCA1 and 
BRAC2 genes operate as tumor-suppressor genes have been identified as main contributors to 
hereditary breast cancer [16, 17].  Mutations in either of these genes account for majority of 
families in multiple cases. Up to 85% confer a lifetime risk of breast cancer in female BRCA1 
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and BRAC2 mutation carriers [17].  In addition, other germ line mutations in tumor-suppressor 
genes like PTEN or TP53 genes has been implicated to increase susceptibility to breast cancer 
[16]. 
Of all the cases, the most widespread is sporadic breast cancer which is non-hereditary. 
Sporadic cases occur due to gradual accumulation of uncorrected and acquired mutations in 
somatic mutations during lifetime [14, 18]. 
One of the most important oncogenes essential in development of breast cancer is tyrosine 
kinase ERBB2, which belongs to ERBB family. Approximately 60% of in situ carcinomas are 
excessively amplified in ERBB2 [19]. It has been found that over expression of ERBB2 can 
lead to tumorigenesis, transformation and metastasis. Growth factors like EGF and TGFβ can 
also be involved in mammary growth and differentiation at different stages of development 
[14].  
 
Breast cancer in perspective of somatic mosaicism 
Somatic mosaicism implies the presence of genetically distinct lineages of somatic cells in a 
single organism that are resulting from same zygote. The term mosaicism can be used to all 
types of aberrations from point mutations to aneuploidies. Humans develop from a single cell. 
From this single cell an individual grows up to 1013 to 1014 cells. During the growth cells 
undergo many cell divisions and as a result much somatic mutation occurs. These mutations 
occurring during the development likely have major consequences for genetic mosaicism in the 
body and for the risk of cancer that occur from those mutations [20, 21]. The remarkable 
evolutionary history has been hidden by the difficulty of measuring the genetic changes in the 
cell. Recently new high-throughput technologies are just opening up the possibility of 
measuring somatic mutations and evolution [22]. To understand the evolutionary history of an 
individual and cause of disease, somatic genomics must be considered within the context of 
rate and pattern evolutionary changes in cell lineages.    
In biology, during the past several years, germ-line and somatic mosaicism have emerged as 
important factors that put in phenotypic variability. More than 30 monogenic disorders show 
variable expressivity due to somatic mosaicism [23].  Mosaicism also leads to certain aspects 
like embryo twinning and mitochondrial disorders which is a principle cause of antigenic 
diversity [24, 25].  It was proposed that neoplasm results from a single cell which undergoes 
genetic changes and later studies on nucleotides and chromosomes proved the existence of 
somatic mutation in most cancers [26]. Unregulated cell divisions occur due to the 
accumulation of somatic mutation in certain pathways [27]. The difference between somatic 
mosaicism and germline mosaicism (gonadal mosaicism) is based upon the findings of 
population of cells which are genetically different in somatic and germline tissue [28].     
Chimerism is a closely related but different term, and should not be confused with mosaicism. 
Chimerism is defined as the presence of two or more cell lines in an organism that are derived 
from different zygotes. During embryogenesis cells from two different embryos might mix. 
Although this is thought to be rare event, but quite common in dizygotic twins. This has been 
shown by transplantation experiments that such chimeric individuals do not reject the graft 
from their twins as foreign [25, 29].  The rate of mosaicism may depend on the particular 
disorder, tissue of origin or selective pressure. More than 83% of patients with inherited 
mutations in fumarylacetoacetate hydrolase (FAH) gene which causes hereditary tyrosinaemia 
type 1 appear to have mosaic liver that have mutant and reverted population of hepatocytes 
[30]. The two monogenic disorders – Blooms syndrome and Fanconi anaemia are used to 
illustrate the cellular basis, clinical importance and mechanistic range of somatic mosaicism 
[31, 32]. Structural abnormalities of chromosomes also cause somatic mosaicism. Cytogenetic 
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studies in more than one-third of patients with Fanconi anaemia have detected clonal variations 
which arise due to failure of cellular mechanisms that prevent non-disjunction or abnormal 
chromosome segregation [33].        
In hemizygous males, certain X-linked disorders like incontinentia pigment and Rett syndrome 
are usually fatal. In rare cases males who survive with these conditions are informative about 
somatic mosaicism. Moreover, in these cases mosaicism for a DNA mutation or chromosome 
can result in survival of male patients [34, 35].       
Monozygotic twins also called identical twins signify an extraordinary source for 
understanding many disorders, phenotypes and complex genetic diseases. Approximately 3% 
of deliveries are twin births, in which ~10% are monozygotic [36, 37]. While most of the 
studies to date have observed that somatic mutations are connected with various forms of 
cancer, but there is mounting proof that other diseases are also caused due to somatic mutation. 
In recent studies multiple somatic mutations was reported in two brothers with Wiskott-Aldrich 
syndrome an immunodeficiency disease [38].     
Another example of somatic mutation and mosaicism is Heteroplasmy, a phenomenon found in 
diseases associated with alterations in human mitochondrial DNA. There are different 
percentages of affected mitochondria in different tissues or cells in within the tissue which was 
found in maternally inherited diabetes and deafness [39].  
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METHODOLOGICAL BACKGROUND 
Genotyping Methods 
Development of new genotyping methods led to advanced studies on genetic variations. The 
process of determining the genetic variants of an individual by means of molecular techniques 
such as SNP microarray technology is called genotyping. The process of microarrays is based 
up on hybridization between two strands, one DNA oligonucleotide and a complementary 
sequence. Standard DNA microarrays are made up of glass or plastic slide which is coated with 
a frame of approximately 200,000 microscopic spots, each subsequent to a gene or DNA 
segment. By using microarrays the expression levels of thousands of genes in a cell can be 
determined by directly measuring the amount of mRNA attached to each probes on the array. 
The fluorescent tags are excited by laser and with microscope and camera the digital image of 
the array is made together. The florescent signal intensity of each spot on the array is calculated 
by computer program and creates a profile of gene expression in the cell.  
The completion of human genome sequence has unraveled the genetic causes of human 
diseases. In recent times, the international HapMap consortium refined collecting SNP 
haplotype information from three major populations [40]. This haplotype and associated tag 
SNP information may help in studying the genetics of may complex diseases. Recent 
development in genotyping technology have allowed in analysis of 100,000 of SNPs across 
hundreds to thousands of samples. Furthermore, whole genome SNP arrays has been used for 
high-resolution analysis of loss of heterozygosity (LOH), DNA copy number and other 
chromosomal aberrations in cancer and inherited diseases [41].  
During the past, based upon the comparative genomic hybridization (CGH) several 
technologies have been used to study gain and loss of genomic DNA in cancers and 
developmental disorders. It is well known that physical changes in DNA copy number and/or 
in allelic ratios of particular genomic regions are associated with tumor development [42]. In 
specific, LOH has been widely used in discovery of tumor suppressor genes like RB1, TP53 
and WT1 which are involved in formation of retinoblastoma, Li-Fraumeni syndrome and 
Wilm's tumour respectively [43]. Compared to earlier techniques, the introduction of whole 
genome genotyping (WGG) array technology allows combined DNA copy number and LOH 
analysis at high resolutions.   
Nowadays there are different types of commercial SNP arrays available in the market. One of 
them is Illumina Human1M BeadChip. Illumina Human1M BeadChip uses the established 
Infinium assay to profile human genome at more than one million loci, used for detection of 
structural variations (chromosomal aberration) found across the genome. SNP genotyping can 
indicate duplications, deletions and amplifications which can be associated with cancer. 
Illumina Human1M BeadChip detects chromosomal aberrations by comparing the normalized 
intensity of signal (R) of a subject sample and a pool of reference samples. The genomic plots 
of the log2 (R subject / R reference) called log R ratio, and B allele frequency (BAF) value are 
the basis for detection of chromosomal aberrations. By measuring the intensities of signals in 
test DNA versus reference DNA the loss and gain of chromosomal aberrations can be 
identified.  
    
Nimblegen   
High-resolution array CGH has quickly emerged as a method for detection of chromosomal 
abnormalities related with cancer and other complex phenotypes. Nimblegen Human CGH 
3x720K Whole-Genome Tiling array contains empirically tested 720,000 probes per array, 
which provides analysis of whole human genome. The test and reference genomic DNA were 
separately labelled with different fluorescent dyes and co-hybridized to a 720K whole genome 
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tiling array. By using Nimblescan software, the log2-ratio values of the probe signal intensities 
were calculated. The advantages of Nimblegen 720K array are detection of copy number 
variations, segmental duplications and chromosomal aberrations like duplication, deletions and 
amplifications across the genome.         
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AIM 
The main objective of the study was to identify the presence of somatic mosaicism in blood 
and healthy uninvolved margin of breast tissue surrounding the primary tumor in breast cancer 
patients. The validation of the presence of somatic mosaicism was carried out by Nimblegen 
Human CGH 3x720K Whole-Genome Tiling array.  
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MATERIALS AND METHODS  
Assortment of Samples 
A total of 60 pairs of samples blood and uninvolved margin of same breast cancer patient from 
Gdansk were included in this study. Prior to DNA extraction the samples was stored in -70ºC. 
 
DNA extraction from tissue 
A small amount of tissue was taken and chopped with a sterile scalpel. The tissue was 
transferred into a labeled 15 ml falcon tube. To this 4 ml of lysis buffer (10 mM EDTA, pH 
8.0. 10 mM Triscl pH 7.5-8.0 and 50 mM NaCl) was added. The tissue was disrupted with 
Qiagen Tissue Ruptor at full speed until tissue was ruptured thoroughly. Disposable probes for 
each sample were used to prevent cross-contamination. A pinch of proteinase K was added and 
mixed well. Later 500 μl of 10% Sarcosyl was added and mixed gently until the solution 
became viscous. The tubes were incubated overnight at 50ºC. To this equal amount of phenol 
was added and mixed well for 20 min on a suitable mixer. The contents were centrifuged for 10 
min at 4000 rpm in room temperature. Maximum volume of upper phase was transferred to a 
fresh tube; to this equal volume of chloroform+isoamyl alcohol (24:1) was added. The content 
was mixed on suitable mixer for 20 min and centrifuged for 20 min at 4000 rpm in room 
temperature. The upper phase was transferred to a new tube and 1/10 volume of 3 M NaAc was 
added and mixed well. Later twice the volume of 95% ethanol was added and mixed gently by 
inverting tubes for few minutes until precipitate was formed and later incubated in -70ºC for 15 
min. The contents were allowed to thaw and centrifuged at 4000 rpm for 15 min. The 
supernatant was discarded and to this 80% ethanol was added and pellet was washed by 
disrupting and centrifuged at 4000 rpm for 15 min. The wash solution was discarded and the 
pellet was allowed to air dry. As soon as the pellet was dried, based on size of pellet, DNA was 
resuspended in 100-200 μl sterile distilled water.          
 
DNA extraction from blood   
DNA was extracted from blood by using QIAamp DNA Blood Maxi Kit (Qiagen), according 
to manufactures instructions.  
To the empty 50 ml falcon tubes 500 μl protease K was added provided along with kit. The 
blood sample was added to the tubes and volume was brought up to 10 ml by adding PBS. To 
this 12 ml of AL buffer (Lysis buffer) was added and the contents was mixed thoroughly by 
inverting tubes 15 times and vortexing for 1min. The tubes were incubated at 70ºC for 10 min. 
10 ml of 96 % ethanol was added and mixed by inverting the tubes several times and by 
vortexing for 1 min. The obtained volume was transferred to QIAamp Maxi column and 
centrifuged for 3 min at 1850xg (3000rpm). The filtrate was discarded and to the QIAamp 
Maxi column 5 ml of AW1 buffer (wash buffer) was added. The tubes were centrifuged for 1 
min at 4500xg. To this 5ml of AW2 buffer was added and centrifuged for 15 min at 4500xg. 
QIAamp Maxi column was placed into a new 50 ml tubes provided along with kit and to this 
500 μl sterile distilled water was added directly on to the QIAamp Maxi column membrane and 
incubated for 5 min at room temperature and centrifuged for 4500xg for 3min. The eluate was 
transferred into fresh tubes.  
 
Measurement of DNA quality and concentration 
The quality and concentration of DNA extracted from tissue and blood was measured by using 
spectrophotometer- NanoDrop® ND-1000 and Quant-iT™ PicoGreen® dsDNA Assay Kit. 
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Picogreen 
A standard curve was plotted by diluting λ DNA 100 μg/mL provided along with the  Quant-
iT™ PicoGreen® Kits (Molecular Probes™, Invitrogen) with TE buffer (1 mM EDTA and 10 
mM Tris). A series of dilutions from 0.0 to 2000 ng/ml was made (Table:1) 
To the 96 well spectroflourimeter plate 100 μl of the prepared standard dilutions was added.  
1 μl of each DNA sample was added in duplicates and to this 99μl of 1x TE buffer was added. 
The plate was incubated on a shaker for 1 hr at 200rpm. 
 
 
 
 
 
 
 
 
 
 
Table 1: Serial dilutions of λ DNA with their final concentrations used to obtain a standard curve for 
measurement of DNA concentration with picogreen. 
A working solution of picogreen reagent was made by a 200 fold dilution of the concentrated 
DMSO stock with TE-buffer. To achieve 2000ng/ml final concentration of Lambda DNA 40µl 
of stock  DNA was mixed with 1960 µl of TE buffer. 1000 µl from this solution was 
transferred to a tube with 1000 µl of TE buffer. The next step was performed in the same way 
and last solution was left blank. After incubation 100 μl of standard working picogreen solution 
was added to each well containing DNA and to the wells containing standard dilutions. 
Fluorescence was determined by using Wallac 1420 Victor 2 plate reader machine. 
Fluorescence of standard curve was determinate by using Wallac 1420 Victor 2 plates reader 
and plotted in excel (Figure 3). 
 
Figure 3. Lambda DNA standard curve was used to determine the concentration of DNA. The X-axis shows the 
concentration (ng/ml ) and Y-axis depicts florescence signal. The standard curve was made by 10 times serial 
dilutions of the Lambda DNA 
Tube Final 
concentration 
[ng/ml] 
1 2000 
2 1000 
3 500 
4 250 
5 125 
6 62,5 
7 31,25 
8 0 
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Gel electrophoresis 
The quality of the extracted genomic DNA was verified before genotyping. The gDNA was 
analyzed on 0.8% agarose gel with 1 X TAE. Approximately 5 μl gDNA and 2 μl of loading 
dye was added to the wells. The gel electrophoresis was allowed to run for 1 hr at 120 voltes. 
The band size was verified using 1 kb ladder.   
Whole genome genotyping using Illumina 
The extracted DNA from blood and uninvolved margin from breast cancer patients was 
genotyped using Illumina Human1M BeadChip at University of Alabama at Birmingham. 
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RESULTS  
Confirmation of quality of gDNA by gel electrophoresis. 
 The extracted gDNA from 60 pairs of blood and uninvolved margin of breast tissue 
surrounding the primary tumor was run on 0.8% agarose gel (Figure 4). 
 
Figure 4. Agarose gel electrophoresis showing high molecular weight of extracted DNA. Lane 1 1kb ladder; 
lane 2 sample ML36K; lane 3 sample ML36B; lane 4 ML36A2; lane 5 ML36A2. 
 
Illumina genotyping results 
The investigation of somatic mosaicism was based upon the results obtained from Illumina 1M 
DNA analysis BeadChip. The raw data was analyzed using Nexus copy number program, using 
the graphical interface of Nexus software (version 5, BioDiscovery Inc.). The data analyzed by 
the Nexus software for uninvolved margin of breast tissue surrounding primary tumour and 
blood shows the presence of somatic mosaicism in the breast tissue in a given sample (Figure 
5).         
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Figure 5. Whole genome results from breast cancer samples ML36 A (Primary tumour), ML36 K (Blood) and 
ML36 B (Uninvolved margin), profiled with Illumina 1M DNA analysis BeadChip. Panels A,C and E shows 
Log R ratio, while panels B,D and F represents B-allele frequency (BAF) values. Note the difference between log 
ratio and altered B allele frequency indicates the presence of mosaicism in the observed sample.    
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Genotyping results by Nimblegen
 
 
Figure 6. Detection of somatic mosaicism in sample ML36B (uninvolved margin), ML36A2 and ML36A3 using 
NimbleGen CGH 3x720K Whole-Genome Array. The Y axis represents log2 ratios; the X axis represents 
genomic positions along chromosome.  
The results from the Illumina genotyping and Nimblegen show the presence of somatic 
mosaicism in the sample ML36B. The chromosomes 6, 8 and 18 as indicated with arrows 
(Figure 5) show genomic abreactions and this result was compared with the result from 
Nimblegen. The results from Nimblegen show deletion in the chromosome 6, and gain in 
chromosome 8 and chromosome 18 of sample ML36B (uninvolved margin), ML36A2 and 
ML36A3 (primary tumours) (Figure 6).  
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DISCUSSION 
DNA sequences in every nucleated cell of an organism are identical. An adult human is made 
up of ~1014 cells and it is not surprising that errors can occur during DNA replication and cell 
division needed to form a complete individual. In this study in a few set of breast cancer 
samples a remarkable variation was found by using Illumina 1M DNA analysis BeadChip. The 
genotyping data from Illumina indicates that there are variations in the genomic profiles of 
breast tissue surrounding the primary tumour that is health uninvolved margin and blood of 
same patient. The results from NimbleGen 720K microarray also show the presence of genetic 
variations in primary tumour and healthy uninvolved margin of the breast tissue.  
While investigating the whole genome of the breast cancer patients by Illumina genotyping 
numerous genetic variations were observed in few numbers of samples. Over the past few 
years there has been a considerable increase in number of reported cases of somatic mosaicism 
in genetic disease and disorders. In cases where recognition of direct genetic evidence was not 
possible, indirect evidence for possible somatic mosaicism was found in discordant phenotypes 
in monozygotic twins (44, 45). A mutation can also have influence on the phenotype of an 
individual (46). This depends on the particular DNA affected, stage of development and type of 
cells involved. Most of cancers occur due to somatic mutations, and mutations in many other 
diseases like Hemophilia A, Tuberous Sclerosis, Rubinstein-Taybi Syndrome and Chronic 
Granulomatous Disease have shown in some cases to be mosaic either in the patient of one of 
the parents. 
In this study however there is genomic imbalance and presence of somatic variations which 
seem to be more frequent in numerous cohorts of cancer patients. These mutations occur in 
many forms; from point mutation to large structural alterations affecting millions of base pairs 
in the genome. CNVs are subclass of structural variants, commonly defined as region of DNA 
segment more than 1kb that is present a variable number of times in a genome when compared 
to reference genome. These CNVs occur in a proportion of cells where its analysis is more 
demanding. The studies on genetic abnormalities between different populations of somatic 
cells are challenging because the cells might have variant genotypes, probably causing 
phenotypes which can be mixed with other types of normal cells in any tissue. Therefore it is 
necessary to enrich the target cells that have methodological obstacles which requires sorting 
of cells or micro-dissections. 
The application of Illumina beadchips via BAF value as a tool for detection of somatic 
mosaicism on the genome wide scale, introduced an extensive improvement in the detection of 
mosaicism in a range of 5% of affected cells [47]. The rate of discovery of somatic mosaicism 
in the small proportion of studied cells might continue to accelerate the studies on genetic 
heterogeneity of breast malignancies.  
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FUTURE PERSPECTIVES 
The results from this study show the presence of somatic mosaicism. To assess the cause of 
phenotypic expression, somatic mosaicism must be considered. To measure the influence of 
specific gene in particular tissue, the genome sequence of different cells types in large number 
has to be analyzed. Cancer tissues are known to be heterogeneous, it is important to sequence 
all grades and diverse types of tissue surrounding the primary tumour. In specific, 
polymorphisms like CNVs and trinucleotide repeats which are associated with number of 
cancer require a careful genetic analysis of all types of cells that make up tumours.     
Even though techniques such as microarray analysis and high-throughput sequencing analysis 
are readily available, the capability to sequence very specific and possibly a very little number 
of cells will be needed (isolated by e.g. laser capture microdissection) to analyse the phenotype 
expression completely. However, the major outcome of the discovery of somatic mosaicism is 
that we will cease to regard an individual’s genome as fundamentally homogeneous and stable 
throughout individual’s life time. We can view it, to a certain extent, as a structure that 
undergoes considerable changes, such that the genome one is borne with will not remain the 
same when one dies. Research related to metastasis in breast cancer is not well developed. 
Studies that might compare genetic profiles of primary tumour and uninvolved margin may 
lead to identify genomic aberrations in context to cancer development.    
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